Dr. Clay Siegall Shares His Entrepreneurial Experience

Clay Siegall undoubtedly remains one of the current key contributors to the health sector. Founder and CEO of Seattle Genetics, Dr. Siegall has launched significant biotech developments that have brought huge benefits when it comes to cancer healthcare. In one of his recent interviews published by inspirery.com, Clay Siegall shared his entrepreneurial experience with both young and established entrepreneurs.

Asked about his inspiration and how he got into biotech business, Siegall explained that he always had passion for medicine, technology and a drive to innovate alternative healthcare approaches. He specifically got interested in cancer treatment first following a medication experience by a family member. Clay Siegall points out that his initiative was not fully focused on profit generation but to help patients as well as help him be his own boss. The Dr. shared with readers that Seattle Genetics generates revenue through various avenues including sell of drugs, production partnerships, and licensing of the company’s technologies and processes.

Clay Siegall was happy to note that Seattle Genetics’ FDA approved antibody drug conjugate was the first ADC to be approved by FDA. He shares with other entrepreneurs that his company actually became profitable about 10 years after IPO. Like several other successful business leaders, Clay admitted that at some point in business he wasn’t sure on what the future had for Seattle Genetics. His team embraces a unique marketing strategy that involve wine and dinning as well as meetings to negotiate deals and generate new business. Dr. Clay believes that hard work and total commitment has greatly contributed towards his success.

Dr. Clay Siegall

Clay Siegall pursued a B.S in Zoology from the University of Maryland before earning a PhD in Genetics from the famous George Washington University. Before launching Seattle Genetics, Siegall worked with a number of organizations serving in various capacities. He worked with Bristol-Myers Squibb Pharmaceutical Research Institute, National Institute of Health, and National Cancer Institute among several other organizations.

Dr. Siegall established Seattle Genetics in 1998 and has since put it in the global map specializing in targeted therapy. Under his innovative leadership, the company has developed a significant number of products and processes including over 20 drugs. Through its strategic collaborations with Genentech, Bayer, and Pfizer, Seattle Genetics has made tremendous achievements and Siegall believes the future is bright for his business.

The Roles of Clay Siegall in Seattle Genetics

Clay Siegall is the famed founder and celebrated CEO of Seattle Genetics, a leading biotech firm that specializes in developing targeted therapy drugs for diseases that have not shown any significant improvement over the decades. Clay has led the firm towards prosperity since its inception in 1998. He has developed a robust pipeline of over 20 drugs and partnerships with renowned drug manufacturers like Bayer and Pfizer. Clay has grown Seattle Genetics to an authentic power player in the cancer research platform. Moreover, he believes that the old cancer treatment procedure should be replaced with more tolerable and effective targeted drugs.


A Closer Focus on Seattle Genetics


Clay Siegall gave two reasons for founding Seattle Genetics when Inspirery interviewed him. Clay revealed that he was interested in medicine, the power of technology, and the reason to overcome diseases. He was also interested in cancer treatment when he was pursuing zoology at the University of Maryland. Clay realized that cancer treatments like amputation and radical surgery had better treatment options.


Clay mentioned that Seattle Genetics made money from selling its proprietary drugs like ADC, which was approved by Food and Drug Administration. He also revealed that the company became profitable around ten years after the initial public offering (IPO). Clay cited that Seattle Genetics was affected during the depletion phase of the company’s operation capital in 1999 to 2000. He revealed that he overcame that scenario by working through the company’s financial threats. Additionally, Clay confirmed that he was currently successful because of hard work.


Clay Siegall


Clay Siegall has been the esteemed president and talented CEO of Seattle Genetics since 1998. He serves as the Chairman of the Board of Directors of Seattle Genetics. Clay’s leadership has enabled the company to build a diverse pipeline of antibody-based cancer therapies, for instance, ADCETRIS (brentuximab vedotin) that was accredited by the U.S. FDA in 2011.


Previously, Clay worked at National Cancer, National Institute of Health from 1988 to 1991. He later resigned to join Bristol-Myers Squibb Pharmaceutical Research Institute. Clay exited from the company, in 1997, to co-found Seattle Genetics.


Clay serves on the Boards of Director of Alder BioPharmaceuticals, Washington Roundtable, and Ultragenyx Pharmaceutical. Clay pursued a B.S in Zoology from the renowned University of Maryland. He also went to study at George Washington University where he acquired a Ph.D. in Genetics.